Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 for the Treatment of Cryptococcosis
25 juil. 2022 06h30 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids...
Matinas BioPharma to Present at the LD Micro Invitational XII Conference
31 mai 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids...
Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights
12 mai 2022 06h30 HE
|
Matinas BioPharma Holdings, Inc.
– Announced an exclusive research collaboration with BioNTech focused on the combination of mRNA and Matinas’ proprietary LNC platform technology – – 50% of Patients Enrolled to Date in...
Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2022 Financial and Operational Results on May 12, 2022
05 mai 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of...
Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference
03 mai 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids...
BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
11 avr. 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
Exclusive collaboration combines BioNTech’s mRNA vaccine development expertise and Matinas’ Lipid Nanocrystal (LNC) Delivery Platform Technology to advance novel formulations for mRNA vaccines,...
Matinas BioPharma to Present at the Needham Virtual Healthcare Conference
06 avr. 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., April 06, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids...
Matinas BioPharma to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
22 mars 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids...
Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
08 mars 2022 06h30 HE
|
Matinas BioPharma Holdings, Inc.
– Fifteen Patients Enrolled to Date in Cohort 4 of EnACT (all oral induction regimen); Topline Interim Data Expected Q3 2022 – – Potential Pathway to NDA Submission for MAT2203 with Confirmatory Data...
Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial and Operational Results on March 8, 2022
28 févr. 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of...